Evidence map›Paper›PMID 40297584›Full record

ArticleFrontiers in immunology2025

Development and validation of novel models based on clonality immunoglobulin gene rearrangement for evaluation of bone marrow involvement and prognostic prediction in patients with diffuse large B-cell Lymphoma: a multicenter retrospective study.

Zelin Liu, Qianping Li, Ruiqi Liu, Yangyang Ding, Ya Liao, Linhui Hu, Lianfang Pu, Chunhua Zhu, Shenghui Zhang, Shudao Xiong

Abstract readMulticenter Study
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zelin Liu *Hematological Lab, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Qianping Li *Institute of Hematology, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Ruiqi LiuDepartment of Endocrinology, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Yangyang DingHematological Lab, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Ya LiaoHematological Lab, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Linhui HuHematological Lab, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Lianfang PuHematological Lab, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Chunhua ZhuAir Force Health Care Center for Special Services, Hangzhou, Zhejiang, China.
Shenghui ZhangInstitute of Hematology, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Shudao XiongHematological Lab, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Bone marrow involvement (BMI) is a poor prognostic factor in diffuse large B cell lymphoma (DLBCL), and accurate evaluation of BMI is crucial for determining stages and prognosis. This study aimed to identify the most effective examinations for evaluating BMI in DLBCL, including positron emission tomography-computed tomography (PET/CT), immunoglobulin gene rearrangement (IGR), flow cytometry (FCM), bone marrow cytology (BMC) and bone marrow biopsy pathology (BMB), and to further explore its prognostic significance in DLBCL patients. Methods: This retrospective study included 364 newly diagnosed DLBCL patients, all of whom underwent PET/CT, IGR, FCM, BMC, and BMB at diagnosis. Survival outcomes were analyzed via Kaplan-Meier and Cox regression models. Novel prognostic models incorporating combined IGR and BMB results were developed in a training cohort. Results: Compared to other detection methods, Clonal IGR BMI-positive were found the highest rate of 114 patients (31.3%), and IGR BM involvement-positive patients of DLBCL had the worst survival outcomes, especially among patients in stages I to III (P<0.001). Notably, PET/CT existed some limitations in BMI diagnosis, particularly in stage IV patients (P>0.05). Additionally, the combination of IGR and BMB demonstrated superior prognostic predictive capability for the patients in stage IV (PP<0.001). Multivariate analysis further confirmed that double-positive BMI of IGR and BMB was an independent prognostic factors of PFS (P=0.026) and OS (P=0.042). In addition, the novel IPI and NCCN-IPI stratification models were established by incorporating the combination of IGR and BMB in training group. The C-index of novel models were increased when IGR and BMB were supplemented in our cohort. Discussion: Our results suggest that IGR is the most valuable methods for evaluating BMI compared to traditional detection methods. Adding the combination of IGR and BMB to the IPI and NCCN-IPI score may improve their predictive ability. In summary, IGR is essental for evaluation of BMI and provide an ideal method for disease staging and risk stratification in DLBCL patients in the rituximab era.

Indexed as

Bone MarrowGene RearrangementGenes, ImmunoglobulinLymphoma, Large B-Cell, DiffuseAdolescentAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedNeoplasm StagingPositron Emission Tomography Computed TomographyPrognosisRetrospective Studiesbone marrow biopsy pathologybone marrow cytologybone marrow involvementdiffuse large B cell lymphomaflow cytometryimmunoglobulin gene rearrangementpositron emission tomography-computed tomographyprognostic model

Identifiers

PMID40297584
PMCPMC12034632

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.